Press Release - News - k8凯发天生赢家·一触即发

News Center

Share the latest news with you

News Center

Share the latest news with you

Search

2024-09-14 • Press Release

IMPACT Announces Data Presentation of ATRi IMP9064 at ESMO2024

View details
2024-05-16 • Press Release

The Phase 3 clinical trial data of Senaparib has been published in prestigious international journal Nature Medicine, positioning it as a promising first-line maintenance treatment option for the all-comer population in advanced ovarian cancer

View details
2024-03-10 • Press Release

IMPACT Presented the Clinical Data of FLAMES at ESGO Congress

View details
2024-01-11 • Press Release

IMPACT Announces FPD in U.S. of PARP1 selective inhibitor

View details
2023-12-19 • Press Release

IMPACT Entered into Commercial Partnership with Huadong Medicine

View details
2023-11-08 • Press Release

IMPACT Therapeutics Presented the Clinical Data for Senaparib as First-line Maintenance Therapy in Advanced Ovarian Cancer Patients at IGCS Annual Global Meeting 2023 as a Plenary oral Presentation

View details
2023-10-24 • Press Release

IMPACT Therapeutics presented preliminary clinical data of WEE1 inhibitor IMP7068 at ESMO Congress 2023

View details

Previous Page 1 2 3 4 7 Next Page

Address: 27th Floor, New Bund Times Square, 399 Haiyang West Road, Pudong New Area, Shanghai, China

TEL：021-68411121

Email: info@getunderline.com

Address: Room 2506, Jingfeng Center, No. 1698 Shuanglong Avenue, Jiangning District, Nanjing

TEL: 025-52283667

Email: info@getunderline.com

Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 苏ICP备 60370209号苏公网安备 32011202000351 / Clinical Trial Privacy Notice /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement

网站首页 k8凯发天生赢家·一触即发